• Home
  •  / BioSpecifics Technologies

BioSpecifics Technologies

OverviewSuggest Edit

BioSpecifics Technologies is a biopharmaceutical company which engages in the development of an injectable collagenase clostridium histolyticum for multiple indications. The Company offers injectable collagenase in Canada and Australia, as well as in Europe. It also provides injectable collagenase to treat frozen shoulder, cellulite, canine lipoma, lateral hip fat, and plantar fibromatosis, as well as for the treatment of human lipoma and uterine fibroids. The Company is also involved in the development of other clinical indications for which collagenase injection has been tested.

TypePublic
Founded1957
HQLynbrook, USMap
Websitebiospecifics.com

Recent NewsAll News

Latest Updates

Employees (est.) (Dec 2018)5
Revenue (FY, 2018)$33 M(+21%)
Share Price (Nov 2019)$53

BioSpecifics Technologies Office Locations

BioSpecifics Technologies has an office in Lynbrook
Lynbrook, US (HQ)
35 Wilbur St
Show all (1)

BioSpecifics Technologies Financials and Metrics

BioSpecifics Technologies Revenue

BioSpecifics Technologies's revenue was reported to be $32.96 m in FY, 2018
USD

Revenue (Q2, 2019)

8.9m

Net income (Q2, 2019)

6.4m

EBIT (Q2, 2019)

7.0m

Market capitalization (15-Nov-2019)

389.2m

Closing stock price (15-Nov-2019)

53.0

Cash (30-Jun-2019)

14.0m
BioSpecifics Technologies's current market capitalization is $389.2 m.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

11.4m11.1m14.5m14.1m22.8m26.3m27.4m33.0m

Revenue growth, %

15%

General and administrative expense

5.2m4.8m5.0m5.8m7.3m7.9m8.5m8.8m

R&D expense

972.1k1.2m1.5m1.3m1.0m1.3m1.2m756.8k
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Revenue

5.0m1.9m2.6m2.6m2.4m4.0m3.3m3.1m2.8m2.7m4.0m5.6m4.7m6.3m6.6m6.2m6.9m7.7m6.5m6.5m7.1m7.1m8.2m8.1m8.9m

General and administrative expense

1.4m1.2m1.1m1.1m1.4m1.6m1.2m1.1m1.2m1.5m1.8m1.8m1.7m2.2m1.9m1.8m2.4m2.3m2.2m2.1m2.0m2.2m2.9m1.7m

R&D expense

270.8k224.2k249.6k404.3k293.2k294.9k470.0k346.8k382.7k286.3k239.5k256.7k258.8k248.5k444.5k312.9k254.8k337.7k356.8k195.2k211.8k162.6k149.5k161.3k

Operating expense total

1.7m1.5m1.3m1.6m1.7m1.9m1.7m1.4m1.6m1.8m2.0m2.1m2.0m2.4m2.3m2.2m2.7m2.7m2.5m2.3m2.2m2.4m3.1m1.9m
show all
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

3.2m3.4m5.6m9.8m5.1m4.8m7.3m13.2m

Accounts Receivable

3.2m5.1m5.0m3.0m2.5m3.8m4.7m16.5m

Prepaid Expenses

98.2k149.7k326.5k210.8k383.8k623.5k646.7k

Inventories

624.3k
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Cash

5.0m3.8m5.8m3.8m3.8m7.2m4.0m4.6m8.9m8.8m9.7m10.7m8.5m7.5m9.5m7.0m4.7m9.0m6.0m6.4m12.6m13.0m13.4m17.6m14.0m

Accounts Receivable

877.4k1.7m1.8m2.8m3.2m2.9m3.9m5.0m1.9m2.0m3.1m3.7m3.0m4.2m3.8m4.3m3.8m4.9m4.7m4.7m19.2m12.9m14.5m16.5m16.7m

Prepaid Expenses

151.4k122.1k167.3k219.5k161.2k363.9k411.1k444.4k327.9k291.4k382.7k236.7k469.0k258.1k467.1k730.8k554.4k583.6k800.5k673.1k580.9k837.0k802.0k604.4k1.0m

Current Assets

12.9m12.3m14.1m12.7m13.1m15.6m16.4m17.0m19.5m20.3m21.8m29.0m32.7m37.5m48.2m50.6m55.4m55.2m58.4m61.6m82.7m81.4m87.7m101.6m103.0m
show all
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

6.6m3.0m5.3m4.6m9.6m11.4m11.3m20.1m

Depreciation and Amortization

50.7k64.2k64.3k247.1k933.0k1.7m2.2m2.4m

Accounts Payable

(3.0m)(242.2k)121.4k(90.6k)67.3k127.6k195.3k325.6k

Cash From Operating Activities

(687.6k)2.4m5.1m6.1m10.6m16.4m13.2m17.7m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Net Income

6.3m6.5m742.4k1.4m1.9m1.4m2.4m3.6m754.0k1.3m2.7m2.3m4.1m7.0m2.8m5.4m8.5m3.3m6.0m8.7m4.0m8.3m13.9m4.4m10.8m

Depreciation and Amortization

21.2k32.3k12.9k29.0k43.5k16.1k32.2k96.2k89.8k176.6k94.0k172.6k319.6k647.1k414.7k816.1k1.2m545.1k1.1m1.6m699.7k1.4m2.0m153.3k150.6k

Accounts Payable

(1.9m)(2.8m)1.8m97.4k15.6k253.1k147.7k86.2k91.4k(66.5k)(303.2k)239.9k287.7k107.4k26.7k(23.6k)380.9k422.8k423.8k46.6k308.2k118.7k(356.5k)146.1k(1.1m)

Cash From Operating Activities

2.3m758.1k4.1m2.4m2.6m3.9m3.9m3.4m3.9m3.4m4.0m2.0m4.5m6.2m7.4m9.4m14.8m3.3m6.3m9.4m(876.3k)8.1m12.3m6.0m9.8m
show all
USDY, 2019

Financial Leverage

1 x
Show all financial metrics

BioSpecifics Technologies Online and Social Media Presence

BioSpecifics Technologies's Trends

Embed Graph

BioSpecifics Technologies News and Updates

November 15, 2018

BioSpecifics Technologies Corp. Appoints Ron Law, Ph.D, J.D., as Senior Vice President of Business Development

LYNBROOK, N.Y., Nov. 15, 2018 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC) a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first in class collagenase-based product marketed as XIAFLEX® in the U.S. and Xiapex® in...
November 09, 2018

BioSpecifics Technologies Corp. Reports Third Quarter 2018 Financial Results

LYNBROOK, N.Y., Nov. 9, 2018 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first in class collagenase-based product marketed as XIAFLEX® in the U.S. and Xiapex® in...
October 31, 2018

BioSpecifics Technologies Corp. Announces Positive Topline Results from Phase 1 Study of CCH for the Treatment of Uterine Fibroids

LYNBROOK, N.Y., Oct. 31, 2018 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first in class collagenase-based product marketed as XIAFLEX® in the U.S. and Xiapex® in...
August 09, 2018

BioSpecifics Technologies Corp. Reports Second Quarter 2018 Financial Results

LYNBROOK, N.Y., Aug. 9, 2018 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first in class collagenase-based product marketed as XIAFLEX® in the U.S. and Xiapex® in...

BioSpecifics Technologies Blogs

November 08, 2019

BioSpecifics Reports Third Quarter 2019 Financial and Operating Results

- 15% year-over-year increase in royalty revenues for XIAFLEX®
October 23, 2019

Jennifer Chao Appointed Chairperson of BioSpecifics Technologies Corp. Board of Directors

October 10, 2019

BioSpecifics Technologies Corp. Names J. Kevin Buchi as Chief Executive Officer

August 09, 2019

BioSpecifics Technologies Corp. Reports Second Quarter 2019 Financial and Operating Results

- 13% year-over-year increase in royalty revenues for XIAFLEX® -
May 23, 2019

BioSpecifics Technologies Corp. Announces Authorization of up to $4 Million Stock Repurchase Program

May 10, 2019

BioSpecifics Technologies Corp. Reports First Quarter 2019 Financial and Operating Results

- 14% year-over-year increase for BioSpecifics first quarter royalty revenues for XIAFLEX -
Show more

 BioSpecifics Technologies Frequently Asked Questions

  • When was BioSpecifics Technologies founded?

    BioSpecifics Technologies was founded in 1957.

  • How many employees does BioSpecifics Technologies have?

    BioSpecifics Technologies has 5 employees.

  • What is BioSpecifics Technologies revenue?

    Latest BioSpecifics Technologies annual revenue is $33 m.

  • What is BioSpecifics Technologies revenue per employee?

    Latest BioSpecifics Technologies revenue per employee is $6.6 m.

  • Who are BioSpecifics Technologies competitors?

    Competitors of BioSpecifics Technologies include Molecular Partners, Brii Biosciences and ViewPoint Therapeutics.

  • Where is BioSpecifics Technologies headquarters?

    BioSpecifics Technologies headquarters is located at 35 Wilbur St, Lynbrook.

  • Where are BioSpecifics Technologies offices?

    BioSpecifics Technologies has an office in Lynbrook.

  • How many offices does BioSpecifics Technologies have?

    BioSpecifics Technologies has 1 office.